Related Experiment Video
Updated: Jan 19, 2026
Cell-Free Production of Proteoliposomes for Functional Analysis and Antibody Development Targeting Membrane Proteins
Published on: September 22, 2020
Construction and characterization of immunoliposomes targeting fibroblast growth factor receptor 3
Zhong Zheng1, Haotian Ji2, Wenbo Zong1
1Department of Biochemistry and Molecular Biology, College of Basic Medical Science, Jilin University, Changchun, 130021, China.
Abstract:
Fibroblast growth factor receptor 3 (FGFR3) plays an important regulatory role in tumor cell proliferation and drug resistance. FGFR3 is often constitutively active in many tumors. To deliver drugs into tumor cells by targeting FGFR3 will be a promising and potential strategy for cancer therapy. In this study, a novel fusion protein, ScFv-Cys containing a single chain variable fragment (ScFv) and an additional C-terminal cysteine residue, was generated at a rate of 10 mg/L of bacterial culture and purified at 95% by Ni-NTA chromatography. Subsequently, the recombinant ScFv-Cys was coupled with malPEG2000-DSPE and incorporated into liposomes to generate the immunoliposomes. The results indicated that immunoliposomes can specifically deliver the fluorescent molecules, Dio into bladder cancer cells highly expressing FGFR3. In conclusion, we successfully generated FGFR3-specific immunoliposomes, and proved its targeting effect and delivering ability.
Insights
Researchers developed novel FGFR3-specific immunoliposomes for targeted cancer therapy. These immunoliposomes effectively deliver therapeutic agents into bladder cancer cells, offering a promising strategy for drug delivery.
Area of Science:
- Biotechnology
- Cancer Research
- Drug Delivery
Background:
- Fibroblast growth factor receptor 3 (FGFR3) is crucial in regulating tumor cell proliferation and drug resistance.
- Constitutive activation of FGFR3 is common in various cancers, presenting a therapeutic target.
Purpose of the Study:
- To develop novel immunoliposomes targeting FGFR3 for enhanced cancer therapy.
- To evaluate the targeting specificity and drug delivery capability of FGFR3-targeted immunoliposomes.
Main Methods:
- A fusion protein, ScFv-Cys, was generated and purified.
- Recombinant ScFv-Cys was coupled with malPEG2000-DSPE and incorporated into liposomes to create immunoliposomes.
- The targeting ability was assessed using fluorescent molecules in FGFR3-expressing bladder cancer cells.
Main Results:
- The ScFv-Cys fusion protein was successfully produced and purified to 95% purity.
- Immunoliposomes were effectively generated by incorporating the coupled ScFv-Cys.
- Immunoliposomes specifically delivered fluorescent molecules into bladder cancer cells overexpressing FGFR3.
Conclusions:
- Novel FGFR3-specific immunoliposomes were successfully generated.
- The study demonstrated the targeting effect and drug-delivering ability of these immunoliposomes.
- FGFR3-targeted immunoliposomes represent a promising strategy for cancer therapy.
